These positive outcomes are promising for individuals struggling with narcolepsy, as they provide hope for improved management of their condition. However, Harsh says oxybate therapy is not for everyone.
Patients participating in the open-label extension trial had a few months for titration, more than 24 months for stable dosing, and a one-week follow up.